Oncolytics Biotech, Inc (NASDAQ:ONCY) shares, rose in value on Thursday, July 10, with the stock price down by -7.08% to the previous day’s close as strong demand from buyers drove the stock to $1.12.
Actively observing the price movement in the last trading, the stock closed the session at $1.2, falling within a range of $1.05 and $1.18. The value of beta (5-year monthly) was 1.192. Referring to stock’s 52-week performance, its high was $1.53, and the low was $0.33. On the whole, ONCY has fluctuated by 150.67% over the past month.
With the market capitalization of Oncolytics Biotech, Inc currently standing at about $107.71 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-14.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that ONCY’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the price of ONCY currently trading nearly 41.41% and 89.53% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 72.94, while the 7-day volatility ratio is showing 20.99% which for the 30-day chart, stands at 16.56%. Furthermore, Oncolytics Biotech, Inc (ONCY)’s beta value is 1.06.
A comparison of Oncolytics Biotech, Inc (ONCY) with its peers suggests the former has fared considerably weaker in the market. ONCY showed an intraday change of -7.08% in last session, and over the past year, it grew by 22.02%%.
Data on historical trading for Oncolytics Biotech, Inc (NASDAQ:ONCY) indicates that the trading volumes over the past 10 days have averaged 2.05 and over the past 3 months, they’ve averaged 994.74K. According to company’s latest data on outstanding shares, there are 96.60 million shares outstanding.
Nearly 3.20% of Oncolytics Biotech, Inc’s shares belong to company insiders and institutional investors own 9.89% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 2.61 million shares as on 2025-06-13, resulting in a short ratio of 2.09. According to the data, the short interest in Oncolytics Biotech, Inc (ONCY) stood at 305.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 2.23 million. The stock has risen by 8.25% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ONCY stock heading into the next quarter.
